Dystrophin (DMD)-Pipeline Review, H2 2016

Dystrophin (DMD)-Pipeline Review, H2 2016


  • Products Id :- GMDHC0502TDB
  • |
  • Pages: 81
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Dystrophin (DMD)-Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Dystrophin (DMD)-Pipeline Review, H2 2016', provides in depth analysis on Dystrophin (DMD) targeted pipeline therapeutics.

The report provides comprehensive information on the Dystrophin (DMD), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Dystrophin (DMD) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Dystrophin (DMD)

The report reviews Dystrophin (DMD) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Dystrophin (DMD) targeted therapeutics and enlists all their major and minor projects

The report assesses Dystrophin (DMD) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Dystrophin (DMD) targeted therapeutics

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Dystrophin (DMD)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dystrophin (DMD) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Dystrophin (DMD) Overview 8

Therapeutics Development 9

Dystrophin (DMD)-Products under Development by Stage of Development 9

Dystrophin (DMD)-Products under Development by Therapy Area 10

Dystrophin (DMD)-Products under Development by Indication 11

Dystrophin (DMD)-Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Dystrophin (DMD)-Products under Development by Companies 14

Dystrophin (DMD)-Products under Development by Universities/Institutes 16

Dystrophin (DMD)-Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Dystrophin (DMD)-Companies Involved in Therapeutics Development 24

Asklepios BioPharmaceutical, Inc. 24

BioMarin Pharmaceutical Inc. 25

Daiichi Sankyo Company, Limited 26

Genethon 27

Nippon Shinyaku Co., Ltd. 28

PTC Therapeutics, Inc. 29

Sarepta Therapeutics, Inc. 30

WAVE Life Sciences Ltd. 31

Dystrophin (DMD)-Drug Profiles 32

Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Biostrophin-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

BMBD-001-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

DS-5141-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

eteplirsen-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Gene Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Gene Therapy to Activate Dystrophin for Muscular Dystrophy-Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

NS-065-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Oligonucleotides 1 to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Oligonucleotides 2 to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Oligonucleotides 3 to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

PRO-055-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

SGT-001-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

Small Molecule to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

SRP-4008-Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

SRP-4044-Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

SRP-4045-Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

SRP-4050-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

SRP-4052-Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

SRP-4053-Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

SRP-4055-Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Stem Cell Therapy to Activate Dystrophin for Duchenne Muscular Dystrophy-Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

Dystrophin (DMD)-Dormant Projects 69

Dystrophin (DMD)-Discontinued Products 70

Dystrophin (DMD)-Featured News & Press Releases 71

Jun 06, 2016: Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA 71

May 25, 2016: Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date 71

Apr 25, 2016: MDA Chief Medical and Scientific Officer Testifies at Landmark FDA Hearing for Duchenne Drug 71

Apr 25, 2016: Sarepta Issues Statement on Advisory Committee Outcome for Use of Eteplirsen in the Treatment of Duchenne Muscular Dystrophy 72

Mar 14, 2016: Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen 73

Mar 14, 2016: Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy 73

Feb 25, 2016: Daiichi Sankyo Announces Commencement of Clinical Trials in Japan for Duchenne Muscular Dystrophy Treatment 73

Feb 08, 2016: Sarepta Therapeutics Receives Notification of PDUFA Extension for Eteplirsen 74

Jan 20, 2016: FDA Postpones Advisory Committee Meeting to Review Eteplirsen Due to Severe Weather Storm in the Washington D.C. Area 74

Dec 18, 2015: Sarepta Therapeutics Announces FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping 75

Nov 17, 2015: Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology 75

Oct 22, 2015: Gene Therapy Treats All Muscles in the Body in Muscular Dystrophy Dogs 76

Oct 14, 2015: Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy 77

Oct 01, 2015: Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy 77

Aug 25, 2015: Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA for the Potential Treatment of Duchenne Muscular Dystrophy for Patients Amenable to Exon 51 Skipping 79

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Routes of Administration, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 22

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 23

Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016 24

Pipeline by BioMarin Pharmaceutical Inc., H2 2016 25

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 26

Pipeline by Genethon, H2 2016 27

Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 28

Pipeline by PTC Therapeutics, Inc., H2 2016 29

Pipeline by Sarepta Therapeutics, Inc., H2 2016 30

Pipeline by WAVE Life Sciences Ltd., H2 2016 31

Dormant Projects, H2 2016 69

Discontinued Products, H2 2016 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Asklepios BioPharmaceutical, Inc.

BioMarin Pharmaceutical Inc.

Daiichi Sankyo Company, Limited

Genethon

Nippon Shinyaku Co., Ltd.

PTC Therapeutics, Inc.

Sarepta Therapeutics, Inc.

WAVE Life Sciences Ltd.

Dystrophin (DMD) Therapeutic Products under Development, Key Players in Dystrophin (DMD) Therapeutics, Dystrophin (DMD) Pipeline Overview, Dystrophin (DMD) Pipeline, Dystrophin (DMD) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224280
Site License
USD 7000 INR 448560
Corporate User License
USD 10500 INR 672840

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com